Shanghai-area CDMO/CRO providing custom pharmaceutical intermediate and API research and manufacturing services.
Shanghai-area CDMO/CRO providing custom pharmaceutical intermediate and API research and manufacturing services.
Sells a very large catalogue of ready-made chemical building blocks that drug researchers order like parts, so revenue follows the steady stream of discovery work and small repeat orders, not large single contracts. Custom synthesis and manufacturing for drug developers are a smaller add-on.
In one line: A small Chinese pharma-intermediate CDMO.
Moat: narrow (process know-how, switching costs). Chemistry know-how and qualified supply relationships built into a drug's regulatory filing are sticky.
Headquarters: Shanghai, China · Employees: 734
Size Bide Pharmatech (688073.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $801M, the 2583rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥60.91 on 18 Nov 2026.
Performance Over six months the shares gained 10.2%, against -8.3% for the median peer and -20.0% for the China market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 9.9% over the last twelve months (peer median +2.1%); the operating margin is 18.8% (peer median 5.0%).
Valuation It trades at 24.3× forward earnings against a peer median of 10.8× (3rd most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.3 points above its cost of capital (11.5% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.40B | CN¥1.32B | CN¥1.10B | CN¥1.09B | CN¥830M |
| Revenue growth | — | +20% | +1% | +31% | — |
| Gross profit | CN¥691M | CN¥566M | CN¥430M | CN¥414M | CN¥352M |
| EBITDA | n/a | CN¥227M | CN¥154M | CN¥140M | CN¥170M |
| Net income | CN¥196M | CN¥152M | CN¥117M | CN¥110M | CN¥146M |
| Free cash flow | CN¥191M | CN¥12.9M | CN¥74.8M | -CN¥118M | -CN¥8.54M |
| Capital expenditure | CN¥21.6M | CN¥24.3M | CN¥88.3M | CN¥61.1M | CN¥38.4M |
| Total debt | CN¥130M | CN¥141M | CN¥82.4M | CN¥57.3M | CN¥40.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bide Pharmatech 688073.SS | $801M | +10% | +10% | 19% | 24.3× | 13.9% |
| Wuxi Apptec 2359.HK | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% |
| Porton Pharma Solutions 300363.SZ | $1.66B | +37% | +6% | -2% | n/a | 2.1% |
| Asymchem Laboratories (Tianjin) 002821.SZ | $7.27B | +20% | +18% | 17% | 37.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688073.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.0% | -3.7% | 10th highest of 19 |
| 6-month return | +10.2% | -8.3% | 5th highest of 19 |
| Distance from 52-week high | -31.5% | -34.8% | 9th highest of 19 |
| Revenue growth (TTM) | +9.9% | +2.1% | 6th highest of 19 |
| Operating margin | 18.8% | 5.0% | 5th highest of 19 |
| Forward P/E | 24.3× | 10.8× | 3rd most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 13.9% | 4.6% | 4th most demanding of 10 |
| Growth delivered (Del g) | +27.7% | +10.1% | highest of 10 |
| Hurdle (Req g minus delivered) | -13.8 pp | -5.1 pp | 4th least demanding of 10 |
| ROIC minus cost of capital | +7.3 pp | -2.3 pp | 3rd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 24.3× | 13.9% | +27.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 10.8× | 1.5% | +22.1% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 19.6× | 16.3% | -8.7% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 3.7× | -2.6% | +20.3% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 42.2× | 6.6% | +17.7% |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 3.5× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 10.4× | 4.6% | +22.5% |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | n/a | -2.5% | +2.6% |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 252.9× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | n/a | 33.9% | +10.1% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | n/a | -3.8% | -0.8% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | n/a | n/a | n/a |